Pfizer and BioNTech to offer COVID vaccine to volunteers who got placebo By Reuters

© Reuters. FILE PHOTO: Syringes to administer the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen at a nursing home in Burgbernheim

(Reuters) – Pfizer Inc (NYSE:) and its partner BioNTech Se plan to give volunteers who received a placebo in its COVID-19 vaccine trial an option to receive a first dose of the vaccine by March 1, 2021, while staying within the study.

The trial’s Vaccine Transition Option allows all participants aged 16 or older the choice to discover whether they were given the placebo, “and for participants who learn they received the placebo, to have the option to receive the investigational vaccine while staying in the study,” the companies said on their website https://www.covidvaccinestudy.com/participants for trial participants.

The U.S. Food and Drug Administration and a panel of its outside advisers have expressed concerns over Pfizer’s “unblinding” plan, saying it could make it harder to continue collecting data on safety and effectiveness needed to win full FDA approval of the vaccine.

Trial participants who received the placebo will have two doses of the investigational vaccine reserved for them within the study, the companies said on the website.

“The study doctor will follow the latest guidance from the U.S. Centers for Disease Control and Prevention and their local health authorities to offer the Vaccine Transition Option to participants in a prioritized manner,” the companies said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*